Lun Deng-Xing, Hu Yong-Cheng, Xu Zhao-Wan, Xu Li-Na, Wang Bin-Wu
Department of Spine Surgery, Weifang People's Hospital, Guangwen Road, Kuiwen District, Weifang City, Shandong Province, 261041, China.
Tumour Biol. 2014 Feb;35(2):1263-6. doi: 10.1007/s13277-013-1168-2. Epub 2013 Sep 7.
Published studies researching the prognostic significance of ezrin expression in patients with osteosarcoma are inconclusive and heterogeneous. We conducted a meta-analysis to assess its prognostic value more precisely. The hazard ratios with corresponding 95 % confidence intervals were calculated to evaluate the effects. Five studies with 318 osteosarcoma patients were included to estimate the relationship between ezrin and disease-free survival, and ezrin and overall survival. Compared with osteosarcoma patients with low or negative ezrin expression, patients with high ezrin expression tended to be associated with lower disease-free survival, but the difference was not significant. However, patients with high ezrin expression were obviously associated with lower overall survival. Therefore, the findings from this systematic review suggest that ezrin expression is an effective biomarker of prognosis in patients with osteosarcoma.
已发表的关于埃兹蛋白表达在骨肉瘤患者中的预后意义的研究结果尚无定论且存在异质性。我们进行了一项荟萃分析以更精确地评估其预后价值。计算了具有相应95%置信区间的风险比来评估效果。纳入了五项涉及318例骨肉瘤患者的研究，以评估埃兹蛋白与无病生存期以及埃兹蛋白与总生存期之间的关系。与埃兹蛋白表达低或阴性的骨肉瘤患者相比，埃兹蛋白表达高的患者无病生存期往往较低，但差异不显著。然而，埃兹蛋白表达高的患者总生存期明显较低。因此，该系统评价的结果表明，埃兹蛋白表达是骨肉瘤患者预后的有效生物标志物。
